WO2010041617A1 - β-アミロイド前駆体蛋白質由来マトリックスメタロプロテアーゼ-2インヒビターペプチドと組織メタロプロテアーゼ阻害物質との融合タンパク質 - Google Patents
β-アミロイド前駆体蛋白質由来マトリックスメタロプロテアーゼ-2インヒビターペプチドと組織メタロプロテアーゼ阻害物質との融合タンパク質 Download PDFInfo
- Publication number
- WO2010041617A1 WO2010041617A1 PCT/JP2009/067320 JP2009067320W WO2010041617A1 WO 2010041617 A1 WO2010041617 A1 WO 2010041617A1 JP 2009067320 W JP2009067320 W JP 2009067320W WO 2010041617 A1 WO2010041617 A1 WO 2010041617A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmp
- fusion molecule
- timp
- inhibitor
- app
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Definitions
- the present invention relates to a fusion protein of a matrix metalloproteinase-2 inhibitor peptide derived from ⁇ -amyloid precursor protein and a tissue metalloprotease inhibitor, and uses thereof, and more particularly, to a matrix metalloproteinase-2 of ⁇ -amyloid precursor protein molecule
- the present invention relates to a fusion molecule comprising a selective inhibitory active region and a tissue metalloprotease inhibitor capable of binding to latent matrix metalloprotease-2 and use thereof.
- Matrix metalloproteases are proteolytic enzymes having high degrading activity for extracellular matrix proteins, and are thought to support cell migration when cancer invades and metastasizes (Non-patent Document 1).
- MMP-2 promotes angiogenesis in cancer tissues (Non-patent Document 2). Therefore, MMPs are the preferred target molecules for the development of cancer metastasis inhibitors and cancer growth inhibitors.
- MMP inhibitors based on hydroxamic acid derivatives have been developed mainly by pharmaceutical companies. It was.
- MMPs inhibitors that have been developed so far inhibit MMPs other than the target MMP in vivo and exhibit unexpected side effects due to their low specificity. For this reason, most pharmaceutical companies are now withdrawing from MMPs inhibitor development. In addition, some MMPs suppress cancer invasion and metastasis. When all MMPs are inhibited by inhibitors with low specificity, the effect of suppressing the target MMP activity is offset. Even the possibility of promoting cancer metastasis has been shown.
- An object of the present invention is to provide a substance capable of specifically inhibiting MMP-2.
- APP-IP ISYGNDALMP sequence
- MMP-2 ⁇ -amyloid precursor protein
- the gist of the present invention is as follows.
- a fusion molecule comprising a matrix metalloproteinase-2 selective inhibitory active region of a ⁇ -amyloid precursor protein molecule and a tissue metalloprotease inhibitor capable of binding to latent matrix metalloproteinase-2.
- a transformant comprising the vector according to (5).
- a pharmaceutical composition comprising the fusion molecule according to (1).
- a cancer metastasis and / or angiogenesis inhibitor comprising the fusion molecule according to (1).
- a therapeutic and / or prophylactic agent for cardiovascular disease comprising the fusion molecule according to (1).
- the therapeutic and / or prophylactic agent according to (10), wherein the cardiovascular disease is selected from the group consisting of myocardial infarction, arteriosclerosis and hypertrophic cardiomyopathy.
- a matrix metalloproteinase-2 inhibitor containing the fusion molecule according to (1) (12) A matrix metalloproteinase-2 inhibitor containing the fusion molecule according to (1). (123) A method for suppressing cancer metastasis and / or angiogenesis, comprising administering the fusion molecule according to (1). (14) A method for treating and / or preventing a circulatory system disease, comprising administering the fusion molecule according to (1). (15) A method for inhibiting matrix metalloproteinase-2, comprising using the fusion molecule according to (1). (16) The fusion molecule according to (1) for use as a medicament. (17) The fusion molecule according to (1) for use in suppressing cancer metastasis and / or angiogenesis.
- the fusion protein of the present invention is a highly specific MMP-2 inhibitor, so this inhibitor has very few side effects and is an effective cancer metastasis inhibitor and blood vessel. There is a high possibility that it can be used as a newborn inhibitor.
- the fusion protein of the present invention is an MMP-2 inhibitor with high affinity and high specificity.
- the present invention relates to a matrix metalloproteinase-2 selective inhibitory active region (APP-IP) of a ⁇ -amyloid precursor protein molecule and a tissue metalloprotease capable of binding to latent matrix metalloproteinase-2 (latent MMP-2) Fusion molecules comprising an inhibitor (TIMP) are provided.
- APP-IP matrix metalloproteinase-2 selective inhibitory active region
- latent MMP-2 tissue metalloprotease capable of binding to latent matrix metalloproteinase-2
- APP-IP is a partial amino acid sequence (ISYGNDALMP sequence) in the ⁇ -amyloid precursor protein (APP) molecule, and MMP-2 has selective inhibitor activity (THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 278, No. (16, April 18, pp. 14020-14028,282003).
- This APP-IP inhibits MMP-2 activity in a different inhibition mode than conventional hydroxamic acid MMPs inhibitors and natural inhibitor proteins TIMPs.
- hydroxamic acid MMPs inhibitors and TIMPs interact in the same N-terminal-C terminal orientation as the substrate peptide, but APP-IP interacts with this N-terminal-C. It interacts so that the terminal orientation is reversed (THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 283, No. 15, April 11, pp. 10068-10078, 2008).
- the organism derived from APP-IP is preferably a human, but is not limited to a human and may be other mammals (mouse, rat, hamster, rabbit, cat, dog, cow, horse, sheep, monkey, etc.).
- Human MMP-2 is biosynthesized intracellularly and then secreted to the outside of the cell. Immediately after secretion, it consists of 631 amino acid residues and is called a “propeptide region” on the N-terminal side in the molecule. Has an intramolecular inhibitor region consisting of amino acid residues. This type of MMP-2 is called "latent type”. Latent MMP-2 has no enzymatic activity due to the presence of the propeptide region. In addition, inhibitors such as TIMPs cannot bind to the catalytic active site of latent MMP-2.
- the intramolecular inhibitor is peeled off and has enzymatic activity.
- a type consisting of 551 amino acid residues from which 80 amino acid residues on the N-terminal side of latent MMP-2 have been removed is referred to as active MMP-2.
- TIMP-2, 3 and 4 tissue metalloprotease inhibitors 2, 3, 4
- the C-terminal region of TIMP-2, 3 and 4 can bind to the hemopexin-like region of MMP-2.
- Tissue metalloprotease inhibitor 2 (TIMP-2) is a physiological protein inhibitor against MMPs and has inhibitory activity against almost all MMPs (Murphy, G., and Nagase, H. (2006) Cardiovasc. Res) . 69, 562-573).
- TIMP-2 promotes activation of latent MMP-2 catalyzed by cell membrane-bound type-1 MMP (MT1-MMP).
- MT1-MMP cell membrane-bound type-1 MMP
- the mechanism for promoting activation of latent MMP-2 by TIMP-2 is first concentrated on the cell membrane while latent MMP-2 forms a trimolecular complex with TIMP-2 and MT1-MMP.
- the N-terminal region which is the inhibitor active site of TIMP-2, binds to the active site of MT1-MMP, and latent MMP- is bound to the C-terminal region which is not the inhibitor active site of TIMP-2.
- Two hemopexin-like regions are bound.
- MT1-MMP molecules that are not bound to TIMP-2 on the same cell membrane are activated by limited degradation of latent MMP-2 concentrated on the cell membrane (Strongin, A. Y., Collier, I. , Bannikov, G., Marmer B. L., Grant, G. A., and Goldberg, G. I. (1995) J. Biol. Chem. 270, 5331-5338).
- TIMP-2 nucleotide sequence (registration number; NM003255.4 database; NCBI) (SEQ ID NO: 3) Amino acid of TIMP-2 (registration number; NP003246.1 database; NCBI) (SEQ ID NO: 4)
- the amino acid sequence and base sequence of human TIMP-2 are shown in SEQ ID NOs: 4 and 3, respectively.
- TIMP-2 is biosynthesized in the cell, then the signal peptide is cleaved and secreted outside the cell (this becomes an active mature form), so Met is present at the N-terminus immediately after biosynthesis. After the secretion, the 27th Cys is number 1. The numbering of amino acid residues of TIMP-2 is usually based on the mature type.
- the amino acid sequence of SEQ ID NO: 4 contains a signal peptide (positions 1 to 26) at the N-terminus.
- SEQ ID NO: 3 is the base sequence of DNA encoding the amino acid sequence of SEQ ID NO: 4.
- Tissue metalloprotease inhibitors 3 and 4 are physiological protein inhibitors for MMPs as well as TIMP-2, and have inhibitory activity against almost all MMPs.
- TIMP-3 also inhibits the activity of metalloproteases belonging to families other than MMPs such as ADAM10, ADAM12, ADAM17 and ADAM-TS1, ADAM-TS4, and ADAM-TS5.
- TIMP-3 and TIMP-4 can bind to regions other than the catalytically active site of MMP-2 in the same manner as TIMP-2 (Murphy, G., and Nagase, H. (2006) Cardiovasc. Res. 69, 562-573).
- TIMP-3 nucleotide sequence (registration number; NM_000362.4 database; NCBI) (SEQ ID NO: 10) TIMP-3 amino acid sequence (registration number; NP_000353.1 database; NCBI) (SEQ ID NO: 11) TIMP-4 nucleotide sequence (registration number; NM_003256.2 database: NCBI) (SEQ ID NO: 12) TIMP-4 amino acid sequence (registration number; NP_003247.1 database; NCBI) (SEQ ID NO: 13)
- the amino acid sequence and base sequence of human TIMP-3 are shown in SEQ ID NOs: 11 and 10, respectively.
- TIMP-3 Since TIMP-3 is biosynthesized in the cell, the signal peptide is cleaved and secreted outside the cell (this becomes an active mature form), so Met is present at the N-terminus immediately after biosynthesis. After secretion, the 24th Cys is number one. The numbering of amino acid residues in TIMP-3 is usually based on the mature form.
- the amino acid sequence of SEQ ID NO: 11 contains a signal peptide (positions 1 to 23) at the N-terminus.
- SEQ ID NO: 10 is the base sequence of DNA encoding the amino acid sequence of SEQ ID NO: 11.
- the amino acid sequence and base sequence of human TIMP-4 are shown in SEQ ID NOs: 13 and 12, respectively. After TIMP-4 is biosynthesized in the cell, the signal peptide is cleaved and secreted outside the cell (this becomes an active mature form), but Met is present at the N-terminus immediately after biosynthesis. After the secretion, the 30th Cys is number one. The numbering of amino acid residues of TIMP-4 is usually based on the mature type.
- the amino acid sequence of SEQ ID NO: 13 contains a signal peptide (positions 1 to 29) at the N-terminus.
- SEQ ID NO: 12 is the base sequence of DNA encoding the amino acid sequence of SEQ ID NO: 11.
- TIMP-2, 3 and 4 are derived.
- the organism from which TIMP-2, 3 and 4 are derived is preferably human, but is not limited to humans, and other mammals (mouse, rat, hamster, rabbit, cat, dog, cow, horse, sheep, monkey, etc.) May be.
- 1 to 10 preferably 1 to 6, more preferably 1 to 3 amino acids may be added to the N-terminal and / or C-terminal of APP-IP.
- Such amino acid addition prevents the signal peptidase from being cleaved within the APP-IP sequence by adding an N-terminal amino acid during biosynthesis of the fusion protein using eukaryotic cells. It has the purpose of preventing the APP-IP moiety from being removed by the action of aminopeptidase.
- insertion of a glycine residue on the C-terminal side introduces a flexible spacer between the TIMP body that can bind to latent MMP-2 and the APP-IP part, and TIMP that can bind to latent MMP-2.
- the APP-IP moiety on the N-terminal side of TIMP that can bind to latent MMP-2 efficiently approaches the active site of MMP-2 It is made for the purpose.
- amino acid or peptide to be added to the N-terminus of APP-IP AGG, AGGG, AAGG, AAGGG and the like are preferable, but not limited thereto.
- amino acid or peptide added to the C-terminal of APP-IP GG, GGG, GGGG and the like are preferable, but not limited thereto.
- TIMP that can bind to latent MMP-2 should be added to the C-terminal side of APP-IP.
- the fusion protein of APP-IP and TIMP that can bind to latent MMP-2 is complementary to the MMP-2 binding site of TIMP that can bind to latent MMP-2 and the MMP-2 selective inhibition site of APP-IP
- the present inventor has revealed that it can be an MMP-2 inhibitor with high affinity and high specificity by being utilized in an effective manner (see Examples described later).
- Catalytic activity of MMP-2 and its inhibitory effect on its activity are in accordance with the past literature (THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 278, No. 16, April 18, pp. 14020-14028, 2003) It is possible to measure using a substrate.
- the amino acid sequence of an example of a fusion protein of APP-IP and TIMP that can bind to latent MMP-2 (a fusion protein of APP-IP and TIMP-2 prepared in the examples described later) is shown in SEQ ID NO: 6. .
- This amino acid sequence has a TIMP-2 signal sequence (positions 1 to 26) at the N-terminus.
- the amino acid sequence of AAGG is added to the N-terminus of APP-IP and GGG is added to the C-terminus.
- the signal sequence positions 1 to 26
- the mature amino acid sequence is shown in SEQ ID NO: 7.
- the “fusion molecule of APP-IP and TIMP capable of binding to latent MMP-2” of the present invention includes not only the mature form but also those having a signal sequence.
- Mutants that retain the function of a fusion protein of APP-IP and TIMP that can bind to latent MMP-2 (for example, in the amino acid sequence of a fusion protein of APP-IP and TIMP that can bind to latent MMP-2) It consists of an amino acid sequence in which one or several (usually within 50, preferably within 10) amino acids have been deleted, substituted or added, and APP-IP and TIMP capable of binding to latent MMP-2 Proteins having the same biological activity as fusion proteins) are also encompassed by the present invention. Examples of the biological activity of the fusion protein of APP-IP and TIMP capable of binding to latent MMP-2 include MMP-2 inhibitor activity.
- a fusion protein of APP-IP and TIMP that can bind to latent MMP-2 can be produced by a known method. For example, DNA encoding a fusion protein of APP-IP and TIMP that can bind to latent MMP-2 is obtained, and the resulting DNA is incorporated into an appropriate expression vector, introduced into an appropriate host, and transformed.
- a fusion protein can be produced by culturing the prepared host and producing it as a recombinant protein (for example, Satoshi Saigo and Yoko Sano, CURRENT PROTOCOLS Compact Edition, Molecular Biology Experiment Protocol, I, II, III, Maruzen Co., Ltd .: See original, Ausubel, FM, etc., Short Protocols in Molecular Biology, Third Edition, John Wiley & Sons, Inc., New York).
- a recombinant protein for example, Satoshi Saigo and Yoko Sano, CURRENT PROTOCOLS Compact Edition, Molecular Biology Experiment Protocol, I, II, III, Maruzen Co., Ltd .: See original, Ausubel, FM, etc., Short Protocols in Molecular Biology, Third Edition, John Wiley & Sons, Inc., New York).
- the fusion protein of the present invention can also be produced according to a known peptide synthesis method.
- the present invention provides DNA encoding a fusion protein of APP-IP and TIMP that can bind to latent MMP-2.
- the isolated DNA encoding the fusion protein of APP-IP and TIMP that can bind to latent MMP-2 is a nucleotide that encodes the fusion protein of APP-IP and TIMP that can bind to latent MMP-2. Any material containing a sequence may be used.
- DNA encoding the fusion protein comprising the DNA represented by the base sequence of SEQ ID NO: 5 and the amino acid sequence of SEQ ID NO: 6 (amino acid sequence of the fusion protein of human-derived APP-IP and TIMP-2) (for example, TIMP (for example, TIMP-2) that hybridizes with DNA complementary to the DNA (SEQ ID NO: 5) under stringent conditions and can bind to APP-IP and latent MMP-2 And a DNA encoding a protein having the same biological activity as the fusion protein.
- the biological activity of the fusion protein of APP-IP and TIMP capable of binding to latent MMP-2 include MMP-2 inhibitor activity.
- DNA that hybridizes under stringent conditions with DNA complementary to the DNA encoding the fusion protein consisting of the amino acid sequence of SEQ ID NO: 6 is complementary to DNA encoding the fusion protein consisting of the amino acid sequence of SEQ ID NO: 6
- Hybridization is performed under stringent conditions.
- the stability of the nucleic acid duplex or hybrid is expressed by the melting temperature Tm (the temperature at which the probe dissociates from the target DNA). This melting temperature is used to define stringent conditions. Assuming that the Tm drops by 1 ° C. due to a 1% mismatch, the temperature of the final wash of the hybridization reaction must be lowered.
- the final washing temperature must be lowered by 5 ° C.
- the Tm will vary between 0.5 and 1.5 ° C.
- An example of stringent conditions is to hybridize in 5x °C SSC / 5x Denhardt solution / 1.0% SDS at 68 ° C and wash in 0.2x SSC / 0.1% SDS at room temperature.
- An example of moderately stringent conditions is a wash in 3x SSC at 42 ° C.
- the salt concentration or temperature can be varied to achieve an optimal level of identity between the probe and the target nucleic acid.
- DNA encoding the fusion protein consisting of the amino acid sequence of SEQ ID NO: 6 a DNA represented by the base sequence of SEQ ID NO: 5 can be exemplified.
- An isolated DNA encoding a fusion protein of APP-IP of the present invention and TIMP (for example, TIMP-2) capable of binding to latent MMP-2 can be produced, for example, as follows. .
- the DNA encoding human TIMP-2 is cleaved at the restriction enzyme sites Eco52 I and Pst ⁇ ⁇ I contained in the base sequence (SEQ ID NO: 3), and then a pair of complementary enzyme sites between the two restriction enzyme sites.
- Synthetic DNA strand (sense side: 5'-GGCCGACGCCGCCGCAGGAGGAATTAGTTATGGTAATGATGCATTAATGCCAGGAGGAGGCTGCA-3 '(SEQ ID NO: 8) and antisense side: 5'-GCCTCCTCCTGGCATTAATGCATCATTACCATAACTAATTCCTCCTGCGGCGGCGTC-3' (SEQ ID NO: 9) And then inserted into E. coli and cloned.
- DNA encoding a fusion protein variant of APP-IP and TIMP capable of binding to latent MMP-2 is obtained by subjecting the desired region of the fusion protein coding region to point mutagenesis. It can be produced by mutating. The coding region of the mutated fusion protein is amplified by PCR. The obtained PCR product is DNA encoding a mutant of a fusion protein of APP-IP and TIMP (for example, TIMP-2) capable of binding to latent MMP-2.
- the present invention provides a vector containing DNA encoding a fusion protein of APP-IP and TIMP that can bind to latent MMP-2.
- a recombinant vector containing a DNA encoding a fusion protein of APP-IP and TIMP capable of binding to latent MMP-2 can be obtained by a known method (for example, Molecular Cloning 2nd Edition, J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989)) by inserting DNA encoding a fusion protein of APP-IP and TIMP capable of binding to latent MMP-2 into an appropriate expression vector.
- plasmids derived from E. coli eg, pBR322, pBR325, pUC12, pUC13, pGACAG
- plasmids derived from Bacillus subtilis eg, pUB110, pTP5, pC194
- yeast-derived plasmids eg, pSH19, pSH15
- Bacteriophages such as phages
- animal viruses such as retroviruses, adenoviruses, and vaccinia viruses
- insect pathogenic viruses such as baculoviruses
- a promoter, enhancer, splicing signal, poly A addition signal, selection marker, SV40 replication origin, etc. may be added to the expression vector.
- the expression vector may be a fusion protein expression vector.
- fusion protein expression vectors are commercially available: pGEX series (Amersham Pharmacia Biotech), pET CBD Fusion System 34b-38b (Novagen), pET Dsb Fusion Systems 39b and 40b (Novagen), pET GST Fusion System 41 and 42 (Novagen).
- a transformant can be obtained by introducing into a host a recombinant vector containing DNA encoding a fusion protein of APP-IP and TIMP that can bind to latent MMP-2.
- the present invention also provides a transformant comprising a recombinant vector containing DNA encoding a fusion protein of APP-IP and TIMP capable of binding to latent MMP-2.
- Hosts include bacterial cells (eg, Escherichia, Bacillus, Bacillus, etc.), fungal cells (eg, yeast, Aspergillus, etc.), insect cells (eg, S2 cells, Sf cells, etc.), animal cells (eg, CHO cells, COS cells, HeLa cells, C127 cells, 3T3 cells, BHK cells, HEK293 cells, etc.), plant cells and the like.
- bacterial cells eg, Escherichia, Bacillus, Bacillus, etc.
- fungal cells eg, yeast, Aspergillus, etc.
- insect cells eg, S2 cells, Sf cells, etc.
- animal cells eg, CHO cells, COS cells, HeLa cells, C127 cells, 3T3 cells, BHK cells, HEK293 cells, etc.
- the transformant can be cultured in a medium, and a fusion protein of APP-IP and TIMP that can bind to latent MMP-2 can be collected from the culture.
- a fusion protein of APP-IP and TIMP that can bind to latent MMP-2 can be collected from the culture.
- the fusion protein is secreted into the medium, the medium is recovered, the fusion protein is separated from the medium and purified.
- the fusion protein is produced in the transformed cell, the cell may be lysed, and the fusion protein may be separated from the lysate and purified.
- the tag fusion protein is cleaved by treating with FactorXa or enzyme (enterokinase) after separation and purification of the tagged fusion protein A fusion protein can be obtained.
- Separation and purification of the fusion protein can be performed by known methods.
- Known separation and purification methods include methods that utilize differences in solubility such as salting out and solvent precipitation, dialysis, ultrafiltration, gel filtration, and SDS-polyacrylamide gel electrophoresis.
- Method utilizing difference method utilizing charge difference such as ion exchange chromatography, method utilizing specific affinity such as affinity chromatography, method utilizing hydrophobic difference such as reverse phase high performance liquid chromatography
- a fusion protein of APP-IP and TIMP that can bind to latent MMP-2 is used for cancer metastasis and / or angiogenesis inhibitors, cardiovascular diseases (eg, myocardial infarction, arteriosclerosis, hypertrophic cardiomyopathy, etc.) It can be used as a medicine such as a therapeutic and / or prophylactic agent.
- a fusion protein of APP-IP and TIMP capable of binding to latent MMP-2 can be used in vivo or in vitro as a matrix metalloproteinase-2 inhibitor for pharmaceutical or reagent use.
- the present invention includes a pharmaceutical composition comprising a fusion protein of APP-IP and TIMP capable of binding to latent MMP-2, a cancer metastasis and / or angiogenesis inhibitor, a therapeutic and / or prophylactic agent for cardiovascular disease, Also provided are matrix metalloprotease-2 inhibitors.
- MMP-2 matrix metalloproteinase-2
- MMP-2 may be involved not only in cancer invasion / metastasis and angiogenesis in cancer tissues, but also in cardiovascular diseases such as acute myocardial infarction. Therefore, a fusion protein of APP-IP and TIMP that can bind to latent MMP-2 can be applied as a therapeutic agent for these diseases involving MMP-2.
- APP-IP and TIMP-binding protein capable of binding to latent MMP-2 are used to treat cancer metastasis and / or angiogenesis inhibitors, cardiovascular diseases (eg, myocardial infarction, arteriosclerosis, hypertrophic cardiomyopathy, etc.)
- cardiovascular diseases eg, myocardial infarction, arteriosclerosis, hypertrophic cardiomyopathy, etc.
- a fusion protein of APP-IP and TIMP that can bind to latent MMP-2 alone, or a pharmacologically acceptable carrier, diluent or supplement.
- the dosage form it can be administered orally or parenterally to mammals (eg, humans, rabbits, dogs, cats, rats, mice) as a pharmaceutical composition of an appropriate dosage form.
- the dose varies depending on the administration subject, target disease, symptom, administration route, etc., but, for example, when used as a cancer metastasis and / or angiogenesis inhibitor, it can bind to APP-IP and latent MMP-2.
- other parenteral administration for example, nasal administration
- oral administration an equivalent amount can be administered. If symptoms are particularly severe, the dose may be increased according to the symptoms.
- compositions for oral administration include solid or liquid dosage forms, specifically tablets (including dragees and film-coated tablets), pills, granules, powders, capsules (including soft capsules), syrups Agents, emulsions, suspensions and the like.
- Such a composition can be produced by a conventional method, and may contain a carrier, diluent or excipient usually used in the pharmaceutical field.
- carriers and excipients for tablets include lactose, starch, sucrose, and magnesium stearate.
- compositions for parenteral administration include injections and suppositories, and injections include dosage forms such as intravenous injections, subcutaneous injections, intradermal injections, intramuscular injections, and intravenous injections. It is good to be.
- injections are prepared by a conventional method, that is, by dissolving, suspending or emulsifying the fusion protein of the present invention in a sterile aqueous or oily liquid usually used for injections.
- Aqueous solutions for injection include isotonic solutions containing physiological saline, glucose and other adjuvants, and suitable solubilizers such as alcohol (eg, ethanol), polyalcohol (eg, propylene glycol, Polyethylene glycol), nonionic surfactants (for example, polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct-of-hydrogenated-castor-oil)) and the like may be used in combination.
- suitable solubilizers such as alcohol (eg, ethanol), polyalcohol (eg, propylene glycol, Polyethylene glycol), nonionic surfactants (for example, polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct-of-hydrogenated-castor-oil)) and the like may be used in combination.
- suitable solubilizers such as alcohol (eg, ethanol), polyalcohol (eg, propylene glycol, Polyethylene glycol), nonionic surfactants
- the above-mentioned oral or parenteral pharmaceutical composition may be prepared in a dosage unit form suitable for the dose of the active ingredient.
- dosage unit forms include tablets, pills, capsules, injections (ampoules), suppositories, etc., and usually 0.01 to 1 mg of APP-IP and latent MMP for each dosage unit form It preferably contains a fusion protein with TIMP that can bind to -2.
- the content of the active ingredient in the preparation of the dosage unit varies depending on the kind of the preparation, but is usually 1 to 100% by weight, preferably 50 to 100% by weight.
- the above-mentioned pharmaceutical composition may contain other active ingredients as long as an undesirable interaction is not caused by the combination of APP-IP and a fusion protein of TIMP that can bind to latent MMP-2.
- Example 1 Method for producing APP-IP-TIMP-2 fusion protein: DNA encoding human TIMP-2 is cleaved at restriction enzyme sites Eco52 I and Pst I contained in the base sequence (SEQ ID NO: 3), A pair of complementary synthetic DNA strands (sense side: 5'-GGCCGACGCCGCCGCAGGAGGAATTAGTTATGGTAATGATGCATTAATGCCAGGAGGAGGCTGCA-3 '(sequence number 8) and antisense side: 5'-GCCTCCTCCTGGCATTAATGCATCATTACCCTATAACTAATTCCTCCTGCGGCGGCGTC-3' sequence between two restriction enzyme sites The DNA that was double-stranded by annealing was inserted using DNA ligase to prepare DNA encoding the APP-IP-TIMP-2 fusion protein.
- the DNA encoding this protein is used in the animal cell expression vector pcDNA3.1 / Zeo (-) (Invitrogen) or E. coli expression vector pFLAG-CTC (Sigma), respectively. And inserted.
- APP-IP-TIMP-2 fusion protein was obtained by transforming E. coli DH5 ⁇ strain transformed with the above vector (APP-IP-TIMP-2-pFLAG-CTC) at 37 ° C in the presence of 1 mM isopropyl- ⁇ -D-thiogalactopylanoside. By culturing in C for 5 hours, the cells were expressed as inclusion bodies in the cells. The cells were crushed by ultrasonic treatment, and the inclusion bodies were collected by centrifugation.
- APP-IP-TIMP-2 fusion protein recovered as inclusion bodies is dissolved in 50 mM Tris-HCl (pH 8.0) containing 6 M guanidine hydrochloride, 20 mM dithiothreitol, 5 mM EDTA, and insolubles are removed by centrifugation. , Rapidly diffuse in 100 volumes of refolding buffer (50 mM Tris-HCl (pH 8.0), 1 M arginine, 5 mM reduced glutathione, 1 mM oxidized glutathione, 5 mM EDTA), then 4 ° C Incubate for 48 hours to form conformations and intramolecular disulfide bonds. After arginine was removed from this sample by dialysis, APP-IP-TIMP-2 fusion protein in which an intramolecular disulfide bond was formed was isolated and purified using reverse phase HPLC.
- MMP-2, MMP-7, MMP-9 and MT1-MMP catalytic domain synthetic peptide substrate inhibitory effect of APP-IP-TIMP-2 fusion protein on the hydrolytic activity of MMP-2 was strongly inhibited by the fusion protein, and its IC 50 value (the concentration of inhibitor required to inhibit activity by 50%) was about 0.4 nM.
- the activity of MMP-2 was almost completely inhibited in the presence of 2 nM APP-IP-TIMP-2.
- the activity of the MT1-MMP catalytic domain is maintained at about 75% in the presence of 400 nM APP-IP-TIMP-2, and the inhibitory effect of APP-IP-TIMP-2 on MT1-MMP is MMP-2 It was found to be 1/1000 or less compared to the inhibitory effect on On the other hand, from past literature (THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 278, No. 16, April 18, pp.
- TIMP-2 has high inhibitory activity against both MMP-2 and MMP-9, and it has been reported that the respective inhibition constants are 7.2 nM and 43 nM (Olson, MW, Gervasi, DC , Mobashery, S., and Fridman, R. (1997) J. Biol. Chem.
- APP-IP-TIMP-2 did not inhibit MMP-9 at a concentration of 400 nM
- APP-IP-TIMP-2 did not inhibit MMP-9 at a concentration of 400 nM
- the addition of APP-IP to the N-terminus of TIMP-2 completely abolished the MMPs inhibitor activity inherent to TIMP-2.
- This result shows that it is important for the inhibitory activity that the ⁇ -amino group of N-terminal Cys1 of TIMP-2 is coordinated to the zinc ion at the active center of MMP (Fernandez-Catalan, C., Bode, W. , Huber, R., Turk, D., Calvete, JJ, Lichte, A., Tschesche, H., and Maskos, K. (1998) EMBO J.
- MMPs are the preferred target molecules for developing cancer metastasis inhibitors and cancer growth inhibitors.
- MMP inhibitors based on hydroxamic acid derivatives have been developed mainly by pharmaceutical companies.
- MMPs inhibitors that have been developed in the past have been found to inhibit MMPs other than the target MMP in vivo and exhibit unexpected side effects due to their low specificity.
- some MMPs suppress cancer invasion and metastasis.
- the effect of suppressing the target MMP activity is offset. Even the possibility of promoting cancer metastasis has been shown (Overall, C. M., and Kleifeld, O. (2006) Nat. Rev. Cancer 6, 227-239).
- APP-IP-TIMP-2 which is highly specific for MMP-2, is highly likely to be a cancer metastasis inhibitor or cancer growth inhibitor with very few side effects.
- analysis results using knockout mice have reported that MMP-2 deficient mice do not show any apparent damage (Itoh, T., Ikeda, T., Gomi, H., Nakao, S., Suzuki, T., and Itohara, S. (1997) J. Biol. Chem. 272, 22389-22392)
- angiogenesis in cancer tissues is markedly suppressed in MMP-2 deficient mice There is a report (Ito, Ttoet al. (1998) Cancer Res. 58, 1048-1051).
- MMP-2 deficient mice have suppressed cardiac rupture after acute myocardial infarction (Matsumura, S., Iwanaga, S., Mochizuki, S., Okamoto, H., Ogawa, S., and Okada , Y. (2005) J Clin Invest. 115,. 599-609.) And suppression of the development of cardiac hypertrophy induced by blood pressure (Matsusaka, H., Ide, T., Matsushima, S ., Ikeuchi, M.,.
- APP-IP-TIMP-2 fusion protein circulates It can be used as a therapeutic and / or prophylactic agent for systemic diseases.
- the fusion protein of the present invention can be used as an MMP-2 inhibitor with high affinity and high specificity.
- MMP-2 has been suggested to be involved not only in cancer invasion / metastasis and angiogenesis in cancer tissues, but also in cardiovascular diseases such as acute myocardial infarction. Therefore, the fusion protein of the present invention can also be applied as a therapeutic agent for these diseases involving MMP-2.
- this fusion protein can be applied as a reagent for basic research such as analysis of physiological functions of MMP-2.
- SEQ ID NO: 1 shows the base sequence of DNA encoding human APP-IP (region containing residues 586-595 of APP 770 ).
- SEQ ID NO: 2 shows the amino acid sequence of human APP-IP (region containing residues 586-595 of APP 770 ).
- SEQ ID NO: 3 shows the nucleotide sequence of DNA encoding human TIMP-2. This sequence is the base sequence of DNA encoding the amino acid sequence of SEQ ID NO: 4 (the amino acid sequence of human TIMP-2 having a signal peptide (positions 1 to 26) at the N-terminus).
- SEQ ID NO: 4 shows the amino acid sequence of human TIMP-2. This sequence has a signal peptide (positions 1 to 26) at the N-terminus.
- SEQ ID NO: 5 is a fusion protein of human APP-IP (region containing residues 586-595 of APP 770 ) and human TIMP-2 (prepared in the example. Signal peptide (positions 1 to 26) at the N-terminus) And the amino acid sequence of AAGG is added to the N-terminus of APP-IP and the amino acid sequence of GGG is added to the C-terminus).
- SEQ ID NO: 6 is a fusion protein of human APP-IP (region containing residues 586-595 of APP 770 ) and human TIMP-2 (prepared in the example. Signal peptide at positions 1 to 26) And the amino acid sequence of AAGG is added to the N-terminus of APP-IP and GGG is added to the C-terminus).
- SEQ ID NO: 7 shows the amino acid sequence of a fusion protein of human APP-IP (a region containing APP 770 residues 586-595) and human TIMP-2 (the signal peptide is cleaved).
- ⁇ SEQ ID NO: 8> The base sequence of the synthetic DNA strand (sense side) used in the examples is shown.
- ⁇ SEQ ID NO: 9> The base sequence of the synthetic DNA strand (antisense side) used in the examples is shown.
- ⁇ SEQ ID NO: 10> SEQ ID NO: 10 shows the nucleotide sequence of DNA encoding human TIMP-3. This sequence is the base sequence of DNA encoding the amino acid sequence of SEQ ID NO: 11 (the amino acid sequence of human TIMP-3 having a signal peptide (positions 1 to 23) at the N-terminus).
- SEQ ID NO: 11> shows the amino acid sequence of human TIMP-3.
- SEQ ID NO: 12 shows the nucleotide sequence of DNA encoding human TIMP-4.
- This sequence is the base sequence of DNA encoding the amino acid sequence of SEQ ID NO: 13 (the amino acid sequence of human TIMP-4 having a signal peptide (positions 1 to 29) at the N-terminus).
- SEQ ID NO: 13> SEQ ID NO: 13 shows the amino acid sequence of human TIMP-4. This sequence has a signal peptide (positions 1 to 29) at the N-terminus.
Abstract
Description
(1)β-アミロイド前駆体蛋白質分子のマトリックスメタロプロテアーゼ-2選択的阻害活性領域と、潜在型マトリックスメタロプロテアーゼ-2に結合可能な組織メタロプロテアーゼ阻害物質とを含む融合分子。
(2)β-アミロイド前駆体蛋白質分子のマトリックスメタロプロテアーゼ-2選択的阻害活性領域のN末端及び/又はC末端に1~10個のアミノ酸が付加されている(1)記載の融合分子。
(3)潜在型マトリックスメタロプロテアーゼ-2に結合可能な組織メタロプロテアーゼ阻害物質が、組織メタロプロテアーゼ阻害物質2、3及び4からなる群より選択される(1)又は(2)記載の融合分子。
(4)(1)記載の融合分子をコードするDNA。
(5)(4)記載のDNAを含有するベクター。
(6)(5)記載のベクターを含む形質転換体。
(7)(6)記載の形質転換体を培養することを含む、融合分子の製造方法。
(8)(1)記載の融合分子を含有する医薬組成物。
(9)(1)記載の融合分子を含有する癌転移及び/又は血管新生抑制剤。
(10)(1)記載の融合分子を含有する循環器系疾患の治療及び/又は予防薬。
(11)循環器系疾患が、心筋梗塞、動脈硬化及び肥大型心筋症からなる群より選択される(10)記載の治療及び/又は予防薬。
(12)(1)記載の融合分子を含有するマトリックスメタロプロテアーゼ-2阻害剤。
(13)(1)記載の融合分子を投与することを含む、癌転移及び/又は血管新生の抑制方法。
(14)(1)記載の融合分子を投与することを含む、循環器系疾患の治療及び/又は予防方法。
(15)(1)記載の融合分子を使用することを含む、マトリックスメタロプロテアーゼ-2の阻害方法。
(16)医薬として使用するための、(1)記載の融合分子。
(17)癌転移及び/又は血管新生の抑制に使用するための、(1)記載の融合分子。
(18)癌転移及び/又は血管新生抑制剤を製造するための、(1)記載の融合分子の使用。
(19)循環器系疾患の治療及び/又は予防に使用するための、(1)記載の融合分子。
(20)循環器系疾患の治療及び/又は予防薬を製造するための、(1)記載の融合分子の使用。
(21)マトリックスメタロプロテアーゼ-2阻害剤として使用するための、(1)記載の融合分子。
(22)マトリックスメタロプロテアーゼ-2阻害剤を製造するための、(1)記載の融合分子の使用。
従来の低特異性MMPs阻害剤とは異なり、本発明の融合タンパク質は極めて特異性の高いMMP-2インヒビターであることから、このインヒビターは副作用が極めて少なく、かつ、有効な癌転移抑制剤および血管新生抑制剤として利用できる可能性が高い。
TIMP-2のアミノ酸(登録番号; NP003246.1 データベース; NCBI)(配列番号4)
ヒトTIMP-2のアミノ酸配列と塩基配列をそれぞれ配列番号4及び3に示す。TIMP-2は細胞内で生合成された後、シグナルペプチドが切断されて、細胞外に分泌される(これが活性を持つ成熟型となる)ので、生合成直後はMetがN末端に存在するが、分泌後は27番目のCysが1番となる。TIMP-2のアミノ酸残基のナンバリングは成熟型を基とするのが通常となっている。配列番号4のアミノ酸配列は、N末端にシグナルペプチド(1~26番目)を含む。配列番号3は、配列番号4のアミノ酸配列をコードするDNAの塩基配列である。
TIMP-3アミノ酸配列(登録番号; NP_000353.1 データベース; NCBI)(配列番号11)
TIMP-4 塩基配列(登録番号;NM_003256.2 データベース:NCBI)(配列番号12)
TIMP-4アミノ酸配列(登録番号; NP_003247.1 データベース; NCBI)(配列番号13)
ヒトTIMP-3のアミノ酸配列と塩基配列をそれぞれ配列番号11及び10に示す。TIMP-3は細胞内で生合成された後、シグナルペプチドが切断されて、細胞外に分泌される(これが活性を持つ成熟型となる)ので、生合成直後はMetがN末端に存在するが、分泌後は24番目のCysが1番となる。TIMP-3のアミノ酸残基のナンバリングは成熟型を基とするのが通常となっている。配列番号11のアミノ酸配列は、N末端にシグナルペプチド(1~23番目)を含む。配列番号10は、配列番号11のアミノ酸配列をコードするDNAの塩基配列である。
APP-IP-TIMP-2融合タンパク質の製造方法:ヒトTIMP-2をコードするDNAを、その塩基配列(配列番号3)の中に含まれる制限酵素部位Eco52 IおよびPst Iで切断した後、この2つの制限酵素部位の間に一対の相補的な合成DNA鎖(センス側:5'-GGCCGACGCCGCCGCAGGAGGAATTAGTTATGGTAATGATGCATTAATGCCAGGAGGAGGCTGCA-3'(配列番号8)およびアンチセンス側:5'-GCCTCCTCCTGGCATTAATGCATCATTACCATAACTAATTCCTCCTGCGGCGGCGTC-3'(配列番号9))をアニーリングにより2本鎖化したものをDNAリガーゼを用いて挿入し、APP-IP-TIMP-2融合タンパク質をコードするDNAを作製した。このタンパク質をコードするDNAを動物細胞発現用ベクターであるpcDNA3.1/Zeo(-)(Invitrogen社)あるいはE. coli発現用ベクターであるpFLAG-CTC(Sigma社)にそれぞれのマルチクローニング部位を利用して挿入した。 APP-IP-TIMP-2融合タンパク質は上記ベクター(APP-IP-TIMP-2-pFLAG-CTC)で形質転換したE. coli DH5α株を1mMのisopropyl-β-D-thiogalactopylanosideの存在下、37°Cで5時間培養することにより、菌体内に封入体として発現させた。この菌体を超音波処理で破砕し、遠心分離により封入体を回収した。封入体として回収したAPP-IP-TIMP-2融合タンパク質を6Mグアニジン塩酸塩、20 mM dithiothreitol、5 mM EDTAを含む50 mM Tris-HCl (pH 8.0)で溶解し、不溶物を遠心で取り除いた後、100倍容量のリフォールディング緩衝液(50 mM Tris-HCl (pH 8.0)、1 M アルギニン、5 mM 還元型グルタチオン、1mM 酸化型グルタチオン、5 mM EDTA)中に迅速拡散させた後、4°Cで48時間インキュベートすることにより、立体構造および分子内ジスルフィド結合を形成させた。この試料から透析によりアルギニンを除去した後、逆相HPLCを用いて分子内ジスルフィド結合が形成されたAPP-IP-TIMP-2融合タンパク質を単離・精製した。
MMP-2、MMP-7、MMP-9およびMT1-MMP触媒ドメインの合成ペプチド基質水解活性に及ぼすAPP-IP-TIMP-2融合タンパク質の阻害効果を調べた結果、MMP-2の活性が本融合タンパク質により強く阻害され、そのIC50値(活性を50 % 阻害するために要するインヒビターの濃度)は約0.4 nMであった。また、2 nMのAPP-IP-TIMP-2の存在下ではMMP-2の活性はほぼ完全に阻害された。これに対し、MMP-7およびMMP-9の活性は400 nM のAPP-IP-TIMP-2の存在下においてもほぼ100 %に保たれ、全く阻害されない事が判明した(図1)。また、MT1-MMP触媒ドメインの活性は400 nM APP-IP-TIMP-2の存在下、約75 %が保たれており、APP-IP-TIMP-2のMT1-MMPに対する阻害効果はMMP-2に対する阻害効果と比較して、1/1000以下であることが判明した。一方、過去の文献(THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 278, No. 16, April 18, pp. 14020-14028, 2003)からMMP-2、MMP-7、MMP-9およびMT1-MMP触媒ドメインの合成ペプチド基質水解活性に及ぼすAPP-IPの阻害活性はそれぞれのIC50値が30 nM、 15 μM、20 μMおよび2 μMであることから、APP-IP-TIMP-2はAPP-IPに比べ、約75倍高いMMP-2阻害活性を持つのに対し、他のMMPsに対してはAPP-IP-TIMP-2とAPP-IPはほぼ同じ阻害効果を持つことが判明した。これは、APP-IP-TIMP-2融合タンパク質とMMP-2間の相互作用ではTIMP-2部分のC末端領域とMMP-2のヘモペキシン様領域との結合に補助される事により、APP-IP部分とMMP-2の触媒活性部位との相互作用が顕著に促進されたことを示唆している。また、TIMP-2はMMP-2とMMP-9の双方に対して高い阻害活性を持ち、それぞれの阻害定数が7.2 nMおよび 43 nMであることが報告されている(Olson, M. W., Gervasi, D. C., Mobashery, S., and Fridman, R. (1997) J. Biol. Chem. 272, 29975-29983)ことから、APP-IP-TIMP-2が400 nMの濃度でMMP-9を阻害しなかった事実は、 APP-IPをTIMP-2のN末端に付加した事により、TIMP-2が本来持っているMMPsインヒビター活性が完全に消失したことを示唆している。この結果は、TIMP-2のN末端Cys1のα-アミノ基がMMPの活性中心の亜鉛イオンに配位することがその阻害活性に重要であること(Fernandez-Catalan, C., Bode, W., Huber, R., Turk, D., Calvete, J. J., Lichte, A., Tschesche, H., and Maskos, K. (1998) EMBO J. 17, 5238-5248)、このα-アミノ基を化学修飾したり(Higashi, S., and Miyazaki, K. (1999) J. Biol. Chem. 274, 10497-10504)、TIMP-2のN末端にアラニンを1残基付加する(Wingfield, P. T., Sax, J. K., Stahl, S. J., Kaufman, J., Palmer, I., Chung, V., Corcoran, M. L., Kleiner, D. E., and Stetler-Stevenson, W. G. (1999) J. Biol. Chem. 274,21362-21368)と、TIMP-2のMMPs阻害活性が消失するという過去の報告とも良く一致する。以上の結果から、TIMP-2のN末端にAPP-IPを付加すると、特異性の低いTIMP-2のMMPs阻害活性が失われるとともに、APP-IPとMMP-2触媒部位との相互作用が促進され、結果としてMMP-2に対し,高い親和性と特異性をもつ阻害剤ができることが判明した。
配列番号1は、ヒトAPP-IP(APP770の残基586-595を含む領域)をコードするDNAの塩基配列を示す。
<配列番号2>
配列番号2は、ヒトAPP-IP(APP770の残基586-595を含む領域)のアミノ酸配列を示す。
<配列番号3>
配列番号3は、ヒトTIMP-2をコードするDNAの塩基配列を示す。この配列は、配列番号4のアミノ酸配列(N末端にシグナルペプチド(1~26番目)が存在するヒトTIMP-2のアミノ酸配列)をコードするDNAの塩基配列である。
<配列番号4>
配列番号4は、ヒトTIMP-2のアミノ酸配列を示す。この配列は、N末端にシグナルペプチド(1~26番目)が存在する。
<配列番号5>
配列番号5は、ヒトAPP-IP(APP770の残基586-595を含む領域)とヒトTIMP-2との融合タンパク質(実施例で作製したもの。N末端にシグナルペプチド(1~26番目)が存在し、かつAPP-IPのN末端にAAGG、C末端にGGGのアミノ酸配列が付加されている)をコードするDNAの塩基配列を示す。
<配列番号6>
配列番号6は、ヒトAPP-IP(APP770の残基586-595を含む領域)とヒトTIMP-2との融合タンパク質(実施例で作製したもの。N末端にシグナルペプチド(1~26番目)が存在し、かつAPP-IPのN末端にAAGG、C末端にGGGのアミノ酸配列が付加されている)のアミノ酸配列を示す。
<配列番号7>
配列番号7は、成熟型(シグナルペプチドが切断されている)のヒトAPP-IP(APP770の残基586-595を含む領域)とヒトTIMP-2との融合タンパク質のアミノ酸配列を示す。
<配列番号8>
実施例で用いた合成DNA鎖(センス側)の塩基配列を示す。
<配列番号9>
実施例で用いた合成DNA鎖(アンチセンス側)の塩基配列を示す。
<配列番号10>
配列番号10は、ヒトTIMP-3をコードするDNAの塩基配列を示す。この配列は、配列番号11のアミノ酸配列(N末端にシグナルペプチド(1~23番目)が存在するヒトTIMP-3のアミノ酸配列)をコードするDNAの塩基配列である。
<配列番号11>
配列番号11は、ヒトTIMP-3のアミノ酸配列を示す。この配列は、N末端にシグナルペプチド(1~23番目)が存在する。
<配列番号12>
配列番号12は、ヒトTIMP-4をコードするDNAの塩基配列を示す。この配列は、配列番号13のアミノ酸配列(N末端にシグナルペプチド(1~29番目)が存在するヒトTIMP-4のアミノ酸配列)をコードするDNAの塩基配列である。
<配列番号13>
配列番号13は、ヒトTIMP-4のアミノ酸配列を示す。この配列は、N末端にシグナルペプチド(1~29番目)が存在する。
Claims (22)
- β-アミロイド前駆体蛋白質分子のマトリックスメタロプロテアーゼ-2選択的阻害活性領域と、潜在型マトリックスメタロプロテアーゼ-2に結合可能な組織メタロプロテアーゼ阻害物質とを含む融合分子。
- β-アミロイド前駆体蛋白質分子のマトリックスメタロプロテアーゼ-2選択的阻害活性領域のN末端及び/又はC末端に1~10個のアミノ酸が付加されている請求項1記載の融合分子。
- 潜在型マトリックスメタロプロテアーゼ-2に結合可能な組織メタロプロテアーゼ阻害物質が、組織メタロプロテアーゼ阻害物質2、3及び4からなる群より選択される請求項1又は2記載の融合分子。
- 請求項1記載の融合分子をコードするDNA。
- 請求項4記載のDNAを含有するベクター。
- 請求項5記載のベクターを含む形質転換体。
- 請求項6記載の形質転換体を培養することを含む、融合分子の製造方法。
- 請求項1記載の融合分子を含有する医薬組成物。
- 請求項1記載の融合分子を含有する癌転移及び/又は血管新生抑制剤。
- 請求項1記載の融合分子を含有する循環器系疾患の治療及び/又は予防薬。
- 循環器系疾患が、心筋梗塞、動脈硬化及び肥大型心筋症からなる群より選択される請求項10記載の治療及び/又は予防薬。
- 請求項1記載の融合分子を含有するマトリックスメタロプロテアーゼ-2阻害剤。
- 請求項1記載の融合分子を投与することを含む、癌転移及び/又は血管新生の抑制方法。
- 請求項1記載の融合分子を投与することを含む、循環器系疾患の治療及び/又は予防方法。
- 請求項1記載の融合分子を使用することを含む、マトリックスメタロプロテアーゼ-2の阻害方法。
- 医薬として使用するための、請求項1記載の融合分子。
- 癌転移及び/又は血管新生の抑制に使用するための、請求項1記載の融合分子。
- 癌転移及び/又は血管新生抑制剤を製造するための、請求項1記載の融合分子の使用。
- 循環器系疾患の治療及び/又は予防に使用するための、請求項1記載の融合分子。
- 循環器系疾患の治療及び/又は予防薬を製造するための、請求項1記載の融合分子の使用。
- マトリックスメタロプロテアーゼ-2阻害剤として使用するための、請求項1記載の融合分子。
- マトリックスメタロプロテアーゼ-2阻害剤を製造するための、請求項1記載の融合分子の使用。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09819151.3A EP2341138B1 (en) | 2008-10-09 | 2009-10-05 | FUSION PROTEIN COMPOSED OF MATRIX METALLOPROTEINASE-2 INHIBITOR PEPTIDE DERIVED FROM AMYLOID-beta PRECURSOR PROTEIN AND TISSUE INHIBITOR OF METALLOPROTEINASE-2 |
JP2010532896A JP5651474B2 (ja) | 2008-10-09 | 2009-10-05 | β−アミロイド前駆体蛋白質由来マトリックスメタロプロテアーゼ−2インヒビターペプチドと組織メタロプロテアーゼ阻害物質との融合タンパク質 |
US13/123,210 US8802627B2 (en) | 2008-10-09 | 2009-10-05 | Fusion protein composed of matrix metalloproteinase-2 inhibitor peptide derived from amyloid-B precursor protein and tissue inhibitor of metalloproteinase-2 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-262415 | 2008-10-09 | ||
JP2008262415 | 2008-10-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010041617A1 true WO2010041617A1 (ja) | 2010-04-15 |
Family
ID=42100567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/067320 WO2010041617A1 (ja) | 2008-10-09 | 2009-10-05 | β-アミロイド前駆体蛋白質由来マトリックスメタロプロテアーゼ-2インヒビターペプチドと組織メタロプロテアーゼ阻害物質との融合タンパク質 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8802627B2 (ja) |
EP (1) | EP2341138B1 (ja) |
JP (1) | JP5651474B2 (ja) |
WO (1) | WO2010041617A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106496329A (zh) * | 2016-11-04 | 2017-03-15 | 华中科技大学同济医学院附属协和医院 | 一种含有胶原蛋白结合结构域的融合蛋白 |
US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
US10617744B2 (en) | 2015-06-15 | 2020-04-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
US10626399B2 (en) | 2010-01-28 | 2020-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) |
US10688154B2 (en) | 2011-04-08 | 2020-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
US10688130B2 (en) | 2013-12-09 | 2020-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
US11236340B2 (en) | 2010-01-28 | 2022-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990011287A1 (en) * | 1989-03-21 | 1990-10-04 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Matrix metalloproteinase inhibitor peptides |
WO2002050287A2 (en) * | 2000-12-18 | 2002-06-27 | Arriva Pharmaceuticals, Inc. | Multifunctional protease inhibitors and their use in treatment of disease |
WO2007011363A2 (en) * | 2004-08-11 | 2007-01-25 | Trubion Pharmaceuticals, Inc. | Binding domain fusion proteins |
JP2008262415A (ja) | 2007-04-12 | 2008-10-30 | Daiki Sangyo Kk | 先物取引支援システム、先物取引支援サーバ、及び、先物取引支援装置 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7247704B2 (en) | 2000-12-18 | 2007-07-24 | Arriva Pharmaceuticals, Inc. | Multifunctional protease inhibitors and their use in treatment of disease |
-
2009
- 2009-10-05 WO PCT/JP2009/067320 patent/WO2010041617A1/ja active Application Filing
- 2009-10-05 EP EP09819151.3A patent/EP2341138B1/en active Active
- 2009-10-05 JP JP2010532896A patent/JP5651474B2/ja active Active
- 2009-10-05 US US13/123,210 patent/US8802627B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990011287A1 (en) * | 1989-03-21 | 1990-10-04 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Matrix metalloproteinase inhibitor peptides |
WO2002050287A2 (en) * | 2000-12-18 | 2002-06-27 | Arriva Pharmaceuticals, Inc. | Multifunctional protease inhibitors and their use in treatment of disease |
WO2007011363A2 (en) * | 2004-08-11 | 2007-01-25 | Trubion Pharmaceuticals, Inc. | Binding domain fusion proteins |
JP2008262415A (ja) | 2007-04-12 | 2008-10-30 | Daiki Sangyo Kk | 先物取引支援システム、先物取引支援サーバ、及び、先物取引支援装置 |
Non-Patent Citations (22)
Title |
---|
"Current Protocols in Molecular Biology", 1995, JOHN WILEY & SONS |
AUSUBEL, F.M. ET AL.: "Short Protocols in Molecular Biology", JOHN WILEY & SONS, INC. |
FERNANDEZ-CATALAN, C., BODE, W, HUBER, R., TURK, D., CALVETE, J. J., LICHTE, A., TSCHESCHE, H., MASKOS, K., EMBO, vol. 1, no. 17, 1998, pages 5238 - 5248 |
HIGASHI, S. ET AL.: "Identification of a region of beta-amyloid precursor protein essential for its gelatinase A inhibitory activity.", J. BIOL. CHEM., vol. 278, no. 16, 18 April 2003 (2003-04-18), pages 14020 - 14028, XP008136969 * |
HIGASHI, S., MIYAZAKI, K., 1 BIOL. CHEM., vol. 274, 1999, pages 10497 - 10504 |
ITO, T. ET AL., CANCER RES., vol. 58, 1998, pages 1048 - 1051 |
ITO,T. ET AL., CANCER RES., vol. 58, 1998, pages 1048 - 1051 |
ITOH, T., IKEDA, T., GOMI, H., NAKAO, S., SUZUKI, T., ITOHARA, S., J BIOL. CHENZ., vol. 272, 1997, pages 22389 - 22392 |
J. SAMBROOK ET AL.: "Molecular Cloning", 1989, COLD SPRING HARBOR LAB. PRESS |
KAORU SAIGO, YUMIKO SANO: "Current Protocols compact version: Molecular Biology Experimental Protocols I, II and III", MARUZEN |
MATSUMURA, S., IWANAGA, S., MOCHIZUKI, S., OKAMOTO, H., OGAWA, S., OKADA, Y, J CLIN INVEST., vol. 115, 2005, pages 599 - 609 |
MATSUSAKA, H., IDE, T., MATSUSHIMA, S., IKEUCHI, M., KUBOTA, T., SUNAGAWA, K., KINUGAWA, S., TSUTSUI, H., HYPERTENSION., vol. 47, 2006, pages 711 - 717 |
MURPHY, G, NAGASE, H., CARDIOVASC. RES., vol. 69, 2006, pages 562 - 573 |
MURPHY, G., NAGASE, H., CARDIOVASC. RES., vol. 69, 2006, pages 562 - 573 |
OLSON, M. W, GERVASI, D. C., MOBASHERY, S., FRIDMAN, R., J. BIOL. CHEM., vol. 272, 1997, pages 29975 - 29983 |
OVERALL, C. M., KLEIFELD, O., NAT. REV CANCER, vol. 6, 2006, pages 227 - 239 |
SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR PRESS |
STRONGIN, A. Y, COLLIER, I., BANNIKOV, G, MARMER B. L., GRANT, G A., GOLDBERG, G I., J. BIOL. CHEM., vol. 270, 1995, pages 5331 - 5338 |
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 16, 18 April 2003 (2003-04-18), pages 14020 - 14028 |
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, no. 15, 11 April 2008 (2008-04-11), pages 10068 - 10078 |
WERB, Z., CELL, vol. 91, 1997, pages 439 - 442 |
WINGFIELD, P. T, SAX, J. K., STAHL, S. J., KAUFMAN, J., PALMER, I., CHUNG, V, CORCORAN, M. L., KLEINER, D. E., STETLER-STEVENSON,, J. BIOL. CHEM., vol. 274, 1999, pages 21362 - 21368 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
US10626399B2 (en) | 2010-01-28 | 2020-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) |
US11236340B2 (en) | 2010-01-28 | 2022-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3) |
US11912998B2 (en) | 2010-01-28 | 2024-02-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating aging-associated cognitive impairment by reducing CCR3 |
US10688154B2 (en) | 2011-04-08 | 2020-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
US10688130B2 (en) | 2013-12-09 | 2020-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
US10617744B2 (en) | 2015-06-15 | 2020-04-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
US11141469B2 (en) | 2015-06-15 | 2021-10-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
CN106496329A (zh) * | 2016-11-04 | 2017-03-15 | 华中科技大学同济医学院附属协和医院 | 一种含有胶原蛋白结合结构域的融合蛋白 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2010041617A1 (ja) | 2012-03-08 |
US8802627B2 (en) | 2014-08-12 |
EP2341138B1 (en) | 2017-11-22 |
US20110195902A1 (en) | 2011-08-11 |
JP5651474B2 (ja) | 2015-01-14 |
EP2341138A4 (en) | 2012-09-19 |
EP2341138A1 (en) | 2011-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5651474B2 (ja) | β−アミロイド前駆体蛋白質由来マトリックスメタロプロテアーゼ−2インヒビターペプチドと組織メタロプロテアーゼ阻害物質との融合タンパク質 | |
US6610497B1 (en) | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor | |
JP2001517929A (ja) | ペプチド核酸による哺乳動物テロメラーゼの調節 | |
US7195903B2 (en) | Methods for the treatment of thrombosis | |
JP2004506046A (ja) | 骨形成を促進するための方法及び組成物 | |
EP0933423B1 (en) | Meltrins | |
JPH07506959A (ja) | コラーゲン誘発血小板凝集抑制剤 | |
JP4778906B2 (ja) | 膜貫通型酵素阻害物質のスクリーニング方法 | |
KR20220007619A (ko) | 면역조절 조성물 및 방법 | |
US20040203102A1 (en) | Antiplasmin cleaving enzyme | |
JP7075426B2 (ja) | 組織メタロプロテイナーゼ阻害物質3型(timp-3)の変異体、組成物、及び方法 | |
JP2003300906A (ja) | がん転移抑制因子の安定化 | |
Rajan et al. | Presence of an N-Terminal Polyhistidine Tag Facilitates Stable Expression of an Otherwise Unstable N-Terminal Domain of Mouse Tissue Inhibitor of Metalloproteinase-1 inEscherichia coli | |
JP2895626B2 (ja) | 血栓溶解剤 | |
EP2504027B1 (en) | Acceleration of wound healing by a tissue inhibitor of metalloproteinases (timp) linked to glycosylphosphatidylinositol (gpi)-anchors | |
EP3862014A1 (en) | Treatment of panx1 associated diseases | |
WO2005071073A1 (en) | Fap compositions and the use thereof for immunomodulation | |
FR2797890A1 (fr) | Nouvelle metalloprotease matricielle mmp-24 homologue aux stromelysines | |
US20020151481A1 (en) | MMP-2 propeptide for use as antiangiogenic or antitumor agent | |
GB2257974A (en) | Hirudin analogues and process for their preparation | |
JP2002010783A (ja) | 改変型ヒトプロテインcインヒビター | |
NZ530114A (en) | Fibrinolytically active polypeptide | |
JPH06253838A (ja) | ヒト・膵臓エラスターゼiiib | |
WO2012031240A2 (en) | Therapeutics for trauma induced factor v consumptive coagulopathy | |
JPH05968A (ja) | プロテアソーム阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09819151 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010532896 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13123210 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2009819151 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009819151 Country of ref document: EP |